🧫
Longitudinal TLR2 reporter gene study in α-synuclein mice
active
experiment
Created: 2026-04-10T22:34:48
By: etl-v1-backfill
Quality:
50%
✓ SciDEX
ID: exp-2e59e044-73e6-418e-9728-5c3a30daa75e
🧫 Experiment Protocol
ValidationParkinson's diseaseTLR2, SNCAThy1.2-α-synuclein transgenic mice with TLR2 reporter constructproposed
A longitudinal bioluminescence imaging study was conducted using Thy1.2-α-synuclein transgenic mice that expressed a bicistronic DNA construct containing reporter genes (luciferase and green fluorescent protein) under the transcriptional control of the murine toll-like receptor 2 promoter. Monthly imaging revealed progressive increases in TLR2 expression starting from 10 months of age. This experiment provided real-time monitoring of TLR2 activation over time in living animals with α-synuclein pathology, demonstrating that α-synuclein overexpression leads to a progressive microglial response and TLR2 upregulation with age-dependent onset.
PRIMARY OUTCOME
TLR2 promoter activity over time
EXPECTED OUTCOMES
1. The intervention targeting TLR2, SNCA shifts TLR2 promoter activity over time in the predicted direction relative to the matched control arm.
2. Secondary disease-relevant readouts in Parkinson's disease remain directionally concordant with the primary endpoint rather than showing isolated single-assay effects.
3. The effect persists after adjustment for baseline covariates, batch effects, or repeated-measures structure used in the study design.
SUCCESS CRITERIA
- Prespecified primary endpoint (TLR2 promoter activity over time) improves versus control with p < 0.05 or an equivalent corrected threshold used by the study.
- The effect size is biologically meaningful and reproduced across technical/biological replicates or the validation subset.
- Safety, data quality, and missingness remain within protocol-defined bounds so the result is interpretable rather than driven by attrition or assay failure.
PROTOCOL
1. Establish Thy1.2-α-synuclein transgenic mice with TLR2 reporter construct cohorts for Parkinson's disease and predefine inclusion, exclusion, and quality-control criteria before intervention. 2. Apply the experimental manipulation described for TLR2, SNCA, alongside matched control or comparator arms, and document dose, exposure window, and sample timing in a locked protocol log. 3. Measure TLR2 promoter activity over time together with orthogonal secondary readouts such as molecular, imaging, behavioral, or safety endpoints that are appropriate to the title and study design. 4. Use blinded outcome assessment where feasible, prespecified statistical analysis, and replicate the core readout across biological replicates or an independent validation subset. 5. Interpret results against the baseline study rationale: A longitudinal bioluminescence imaging study was conducted using Thy1.2-α-synuclein transgenic mice that expressed a bicistronic DNA construct containing reporter genes (luciferase and green fluorescent protein) under the transcriptional control of the murine
Source: PMID 25522431 ↗
🧫 Experiment Extras
PATHWAY
toll-like receptor 2 signaling, microglial activation
MARKET PRICE
$0.50
STATUS
proposed
▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | experiments |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.